These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26371288)

  • 1. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
    Kramar A; Negrier S; Sylvester R; Joniau S; Mulders P; Powles T; Bex A; Bonnetain F; Bossi A; Bracarda S; Bukowski R; Catto J; Choueiri TK; Crabb S; Eisen T; El Demery M; Fitzpatrick J; Flamand V; Goebell PJ; Gravis G; Houédé N; Jacqmin D; Kaplan R; Malavaud B; Massard C; Melichar B; Mourey L; Nathan P; Pasquier D; Porta C; Pouessel D; Quinn D; Ravaud A; Rolland F; Schmidinger M; Tombal B; Tosi D; Vauleon E; Volpe A; Wolter P; Escudier B; Filleron T;
    Ann Oncol; 2015 Dec; 26(12):2392-8. PubMed ID: 26371288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
    Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
    Ann Oncol; 2015 May; 26(5):873-879. PubMed ID: 25725046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
    Bonnetain F; Bonsing B; Conroy T; Dousseau A; Glimelius B; Haustermans K; Lacaine F; Van Laethem JL; Aparicio T; Aust D; Bassi C; Berger V; Chamorey E; Chibaudel B; Dahan L; De Gramont A; Delpero JR; Dervenis C; Ducreux M; Gal J; Gerber E; Ghaneh P; Hammel P; Hendlisz A; Jooste V; Labianca R; Latouche A; Lutz M; Macarulla T; Malka D; Mauer M; Mitry E; Neoptolemos J; Pessaux P; Sauvanet A; Tabernero J; Taieb J; van Tienhoven G; Gourgou-Bourgade S; Bellera C; Mathoulin-Pélissier S; Collette L
    Eur J Cancer; 2014 Nov; 50(17):2983-93. PubMed ID: 25256896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
    Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
    Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
    Bellera CA; Penel N; Ouali M; Bonvalot S; Casali PG; Nielsen OS; Delannes M; Litière S; Bonnetain F; Dabakuyo TS; Benjamin RS; Blay JY; Bui BN; Collin F; Delaney TF; Duffaud F; Filleron T; Fiore M; Gelderblom H; George S; Grimer R; Grosclaude P; Gronchi A; Haas R; Hohenberger P; Issels R; Italiano A; Jooste V; Krarup-Hansen A; Le Péchoux C; Mussi C; Oberlin O; Patel S; Piperno-Neumann S; Raut C; Ray-Coquard I; Rutkowski P; Schuetze S; Sleijfer S; Stoeckle E; Van Glabbeke M; Woll P; Gourgou-Bourgade S; Mathoulin-Pélissier S
    Ann Oncol; 2015 May; 26(5):865-872. PubMed ID: 25070543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
    Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
    Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.
    Wong SE; Quinn DI; Bjarnason GA; North SA; Sridhar SS
    Am J Clin Oncol; 2020 Aug; 43(8):559-566. PubMed ID: 32398404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
    Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
    J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative clinical end points in rectal cancer--are we getting closer?
    Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
    Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Local recurrence of renal cell carcinoma after nephrectomy].
    Pereverzev AS; Shchukin DV; Iliukhin IuA
    Urologiia; 2003; (6):14-8. PubMed ID: 14708237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
    Tolaney SM; Garrett-Mayer E; White J; Blinder VS; Foster JC; Amiri-Kordestani L; Hwang ES; Bliss JM; Rakovitch E; Perlmutter J; Spears PA; Frank E; Tung NM; Elias AD; Cameron D; Denduluri N; Best AF; DiLeo A; Baizer L; Butler LP; Schwartz E; Winer EP; Korde LA
    J Clin Oncol; 2021 Aug; 39(24):2720-2731. PubMed ID: 34003702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
    Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
    Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
    Kamat AM; Sylvester RJ; Böhle A; Palou J; Lamm DL; Brausi M; Soloway M; Persad R; Buckley R; Colombel M; Witjes JA
    J Clin Oncol; 2016 Jun; 34(16):1935-44. PubMed ID: 26811532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
    Le Tourneau C; Michiels S; Gan HK; Siu LL
    J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice and progress in kidney cancer: methodology for novel drug development.
    Rini BI; Weinberg V; Small EJ
    J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney cancer: overall survival is an unsuitable primary end point.
    Di Lorenzo G; Buonerba C
    Nat Rev Urol; 2010 Jul; 7(7):367-8. PubMed ID: 20616795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.